Astrazeneca Drug Patent Portfolio

Astrazeneca owns 39 orange book drugs protected by 296 US patents with Airsupra having the least patent protection, holding only 1 patent. And Bydureon Pen with maximum patent protection, holding 60 patents. Given below is the list of Astrazeneca's drug patents along with their expiration dates.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12465608	Osimertinib For Use In The Treatment Of Non-Small Cell Lung Cancer	26 Nov, 2042	Active
US11970530	Methods of treating homologous recombination deficient cancer	25 Oct, 2041	Active
US12213988	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	01 Oct, 2041	Active
US12409186	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	01 Oct, 2041	Active
US12213988	Methods of treating chronic kidney disease with dapagliflozin	01 Apr, 2041	Active
US12409186	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	01 Apr, 2041	Active
US10973836	Methods of treating heart failure with reduced ejection fraction	09 Sep, 2040	Active
US11903955	Methods of treating heart failure with reduced ejection fraction	09 Sep, 2040	Active
US10973836	Methods of treating heart failure with reduced ejection fraction	09 Mar, 2040	Active
US11903955	Methods of treating heart failure with reduced ejection fraction	09 Mar, 2040	Active
US11826376	Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same	18 Jan, 2040	Active
US12472194	Methods Of Treating Heart Failure With Preserved Ejection Fraction Employing Dapagliflozin And Compositions Comprising The Same	18 Jan, 2040	Active
US11826376	Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same	18 Jul, 2039	Active
US12472194	Methods Of Treating Heart Failure With Preserved Ejection Fraction Employing Dapagliflozin And Compositions Comprising The Same	18 Jul, 2039	Active
US11331442	Drug delivery systems and related methods	05 Oct, 2038	Active
US11833292	Drug delivery systems and related methods	05 Oct, 2038	Active
US10300065	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction	27 Jul, 2036	Active
US10167291	Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide	01 Jul, 2036	Active
US11059829	Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate	01 Jul, 2036	Active
US9796721	Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide	01 Jul, 2036	Active
US10300065	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction	27 Jan, 2036	Active
US10300087	Extended use zirconium silicate compositions and methods of use thereof	14 Oct, 2035	Active
US11738044	Extended use zirconium silicate compositions and methods of use thereof	14 Oct, 2035	Active
US9592253	Extended use zirconium silicate compositions and methods of use thereof	14 Oct, 2035	Active
US11166951	Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor	11 Aug, 2035	Active
US10272083	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	21 Jan, 2035	Active
US11771696	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	21 Jan, 2035	Active
US10183020	Pharmaceutical compositions comprising AZD9291	02 Jan, 2035	Active
US10683499	Compositions and methods for modulating TTR expression	25 Aug, 2034	Active
US9127276	Conjugated antisense compounds and their use	01 May, 2034	Active
US9181549	Conjugated antisense compounds and their use	01 May, 2034	Active
US10695365	Microporous zirconium silicate for the treatment of hyperkalemia	22 Oct, 2033	Active
US8877255	Microporous zirconium silicate for the treatment of hyperkalemia	22 Oct, 2033	Active
US9913860	Microporous zirconium silicate for the treatment of hyperkalemia	22 Oct, 2033	Active
US10039766	Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide	16 Apr, 2033	Active
US9487525	Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide	16 Apr, 2033	Active
US9353081	Bicyclic Dihydroquinoline-2-One Derivatives	04 Feb, 2033	Active
US10117844	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	04 Jan, 2033	Active
US9050308	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	04 Jan, 2033	Active
US9050309	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	04 Jan, 2033	Active
US8946235	2-(2,4,5-substituted-anilino) pyrimidine compounds	08 Aug, 2032	Active
US11524951	2-(2,4,5-substituted-anilino)pyrimidine compounds	25 Jul, 2032	Active
US9732058	2-(2,4,5-substituted-anilino)pyrimidine compounds	25 Jul, 2032	Active
US10239883	4-imidazopyridazin-1-yl-benzamides as BTK inhibitors	11 Jul, 2032	Active
US9290504	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors	11 Jul, 2032	Active
US9758524	4-imidazopyridazin-1-yl-benzamides as Btk inhibitors	11 Jul, 2032	Active
US8802152	Microporous zirconium silicate for the treatment of hyperkalemia	19 Apr, 2032	Active
US10335432	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032	Active
US10398730	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032	Active
US10413569	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032	Active
US11406662	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032	Active
US8808750	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032	Active
US9844567	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032	Active
US9861658	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032	Active
US8859562	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	04 Aug, 2031	Active
US9616028	Bilayer tablet formulations	12 May, 2031	Active
US8895033	Sustained release formulations using non-aqueous carriers	04 Apr, 2031	Active
US8815258	Compositions, methods and systems for respiratory delivery of two or more active agents	17 Mar, 2031	Active
US8685934	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	26 Nov, 2030	Active
US9616028	Bilayer tablet formulations	12 Nov, 2030	Active
US8425934	Pharmaceutical compositions	17 Oct, 2030	Active
US8895033	Sustained release formulations using non-aqueous carriers	04 Oct, 2030	Active
US8721615	Ampoule comprising an ampoule holder	18 Jul, 2030	Active
US8998876	Ampoule comprising an ampoule holder	07 Jul, 2030	Active
US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Jun, 2030	Active
US9415009	Compositions, methods and systems for respiratory delivery of two or more active agents	28 May, 2030	Active
US10716753	Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems	28 May, 2030	Active
US8324266	Compositions, methods and systems for respiratory delivery of two or more active agents	28 May, 2030	Active
US8703806	Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents	28 May, 2030	Active
US8808713	Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems	28 May, 2030	Active
US9463161	Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems	28 May, 2030	Active
US8685934	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	26 May, 2030	Active
US8425934	Pharmaceutical compositions	17 Apr, 2030	Active
US8101623	Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor	10 Mar, 2030	Active
US8721615	Ampoule comprising an ampoule holder	18 Jan, 2030	Active
US8998876	Ampoule comprising an ampoule holder	07 Jan, 2030	Active
US8475842	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	31 Dec, 2029	Active
US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Dec, 2029	Active
US8690837	Mixing device for a two-chamber ampoule	19 Nov, 2029	Active
US11633396	Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one	07 Oct, 2029	Active
US11975001	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	07 Oct, 2029	Active
US12048695	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	07 Oct, 2029	Active
US12144810	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	07 Oct, 2029	Active
US12178816	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	07 Oct, 2029	Active
US8616196	Inhalation device and a method for assembling said inhalation device	07 Oct, 2029	Active
US8827963	Administering device with holding mechanism	04 Aug, 2029	Active
US8690837	Mixing device for a two-chamber ampoule	19 May, 2029	Active
US8528545	Inhaler device that reduces the risk for miscounting a dosage	16 Apr, 2029	Active
US8616196	Inhalation device and a method for assembling said inhalation device	07 Apr, 2029	Active
US11813246	Pharmaceutical composition	26 Mar, 2029	Active
US12220403	Pharmaceutical composition	26 Mar, 2029	Active
US12318367	Pharmaceutical composition	26 Mar, 2029	Active
US12364684	Pharmaceutical Composition	26 Mar, 2029	Active
US7851502	Pharmaceutical formulations containing an SGLT2 inhibitor	19 Feb, 2029	Active
US8827963	Administering device with holding mechanism	04 Feb, 2029	Active
US7951400	Coated tablet formulation and method	30 Nov, 2028	Active
US8528545	Inhaler device that reduces the risk for miscounting a dosage	16 Oct, 2028	Active
US10059714	Protein kinase B inhibitors	10 Oct, 2028	Active
US10654855	Protein kinase B inhibitors	10 Oct, 2028	Active
US11236095	Protein Kinase B Inhibitors	10 Oct, 2028	Active
US11760760	Protein kinase B inhibitors	10 Oct, 2028	Active
US12252495	Protein kinase B inhibitors	10 Oct, 2028	Active
US9492453	Protein Kinase B Inhibitors	10 Oct, 2028	Active
US8439864	Device for administering fluid from a multi-chamber ampoule in incremental steps	25 Sep, 2028	Active
US9320853	Method for administering a fluid active substance from a multi-chamber ampoule	25 Sep, 2028	Active
US8247416	Phthalazinone derivative	24 Sep, 2028	Active
US8361972	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028	Active
US8221786	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028	Active
US8716251	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028	Active
US7851502	Pharmaceutical formulations containing an SGLT2 inhibitor	19 Aug, 2028	Active
US8216180	Administering apparatus with functional drive element	12 Jul, 2028	Active
US8758292	Administering apparatus with functional drive element	12 May, 2028	Active
US8439864	Device for administering fluid from a multi-chamber ampoule in incremental steps	25 Mar, 2028	Active
US9320853	Method for administering a fluid active substance from a multi-chamber ampoule	25 Mar, 2028	Active
US8221786	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028	Active
US8361972	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028	Active
US8716251	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028	Active
US7425637	N3 alkylated benzimidazole derivatives as MEK inhibitors	13 Mar, 2028	Active
US8216180	Administering apparatus with functional drive element	12 Jan, 2028	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Dec, 2027	Active
US8758292	Administering apparatus with functional drive element	12 Nov, 2027	Active
US8387615	Inhaler cap strap	26 Sep, 2027	Active
US7449464	Phthalazinone derivatives	08 Sep, 2027	Active
US8071579	DNA damage repair inhibitors for the treatment of cancer	12 Aug, 2027	Active
US8143241	DNA damage repair inhibitors for treatment of cancer	12 Aug, 2027	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Jun, 2027	Active
US8387615	Inhaler cap strap	26 Mar, 2027	Active
US8329648	Methods for treating diabetes and reducing body weight	18 Feb, 2027	Active
US8906851	Method for treating diabetes	18 Feb, 2027	Active
US9884092	Methods for treating diabetes and reducing body weight	18 Feb, 2027	Active
US7960370	Type A gelatin capsule containing PUFA in free acid form	20 Dec, 2026	Active
US9156795	Hydrogen sulfate salt	12 Dec, 2026	Active
US9562017	Hydrogen sulfate salt	12 Dec, 2026	Active
US7459554	Imidazopyrazine tyrosine kinase inhibitors	24 Nov, 2026	Active
US7587988	Inhaler device counter	10 Oct, 2026	Active
US8329648	Methods for treating diabetes and reducing body weight	18 Aug, 2026	Expired
US8906851	Method for treating diabetes	18 Aug, 2026	Expired
US9884092	Methods for treating diabetes and reducing body weight	18 Aug, 2026	Expired
US7587988	Inhaler device counter	10 Apr, 2026	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Apr, 2026	Expired
US8101743	Modulation of transthyretin expression	01 Apr, 2026	Expired
US8178693	N3 alkylated benzimidazole derivatives as MEK inhibitors	13 Mar, 2026	Expired
US7456254	Polymer-based sustained release device	30 Dec, 2025	Expired
US8809336	Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors	25 Oct, 2025	Expired
US9006430	Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein	25 Oct, 2025	Expired
US7612176	Polymer-based sustained release device	13 Oct, 2025	Expired
US8431685	Polymer-based sustained release device	13 Oct, 2025	Expired
US8461105	Polymer-based sustained release device	13 Oct, 2025	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2025	Expired
US8628799	Coated tablet formulation and method	13 Jul, 2025	Expired
US9339472	Coated tablet formulation and method	13 Jul, 2025	Expired
US7456254	Polymer-based sustained release device	30 Jun, 2025	Expired
US8875699	Inhaler cap strap	10 May, 2025	Expired
USRE46276	Triazolo(4,5-D)pyrimidine compounds	30 Apr, 2025	Expired
US7612176	Polymer-based sustained release device	13 Apr, 2025	Expired
US8431685	Polymer-based sustained release device	13 Apr, 2025	Expired
US8461105	Polymer-based sustained release device	13 Apr, 2025	Expired
US8383678	Type a gelatin capsule containing PUFA in free acid form	07 Feb, 2025	Expired
US9012501	Type A gelatin capsule containing PUFA in free acid form	07 Feb, 2025	Expired
US9132112	Type A gelatin capsule containing PUFA in free acid form	07 Feb, 2025	Expired
US8875699	Inhaler cap strap	10 Nov, 2024	Expired
USRE46276	Triazolo(4,5-D)pyrimidine compounds	30 Oct, 2024	Expired
US7563871	Polymer-based sustained release device	15 Oct, 2024	Expired
US9238076	Polymer-based sustained release device	15 Oct, 2024	Expired
US7981889	Phthalazinone derivatives	11 Oct, 2024	Expired
US7563871	Polymer-based sustained release device	15 Apr, 2024	Expired
US9238076	Polymer-based sustained release device	15 Apr, 2024	Expired
US8912187	Phthalazinone derivatives	12 Mar, 2024	Expired
US9169235	Phthalazinone derivatives	12 Mar, 2024	Expired
US9566276	Phthalazinone derivatives	12 Mar, 2024	Expired
US8536206	Process for the preparation of roflumilast	08 Mar, 2024	Expired
US8604064	Process for the preparation of roflumilast	08 Mar, 2024	Expired
US8618142	Process for the preparation of roflumilast	08 Mar, 2024	Expired
USRE44186	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	31 Jul, 2023	Expired
US10166247	Composition for inhalation	29 Jul, 2023	Expired
US11311558	Composition for inhalation	29 Jul, 2023	Expired
US7759328	Composition for inhalation	29 Jul, 2023	Expired
US8143239	Composition for inhalation	29 Jul, 2023	Expired
US8575137	Composition for inhalation	29 Jul, 2023	Expired
US6824822	Residual solvent extraction method and microparticles produced thereby	09 Apr, 2023	Expired
US8431154	Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient	19 Feb, 2023	Expired
US9468598	Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient	19 Feb, 2023	Expired
US10166247	Composition for inhalation	29 Jan, 2023	Expired
US11311558	Composition for inhalation	29 Jan, 2023	Expired
US7759328	Composition for inhalation	29 Jan, 2023	Expired
US8143239	Composition for inhalation	29 Jan, 2023	Expired
US8575137	Composition for inhalation	29 Jan, 2023	Expired
US6824822	Residual solvent extraction method and microparticles produced thereby	09 Oct, 2022	Expired
US6858618	Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia	17 Jun, 2022	Expired
US7151102	Phthalazinone derivatives	29 Apr, 2022	Expired
US7223440	Residual solvent extraction method and microparticles produced thereby	03 Mar, 2022	Expired
US7967011	Inhalation device	11 Feb, 2022	Expired
US6858618	Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia	17 Dec, 2021	Expired
US7223440	Residual solvent extraction method and microparticles produced thereby	31 Aug, 2021	Expired
US7967011	Inhalation device	11 Aug, 2021	Expired
US7265124	Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound	09 Jul, 2021	Expired
US6774122	Formulation	09 Jul, 2021	Expired
US7456160	Formulation	09 Jul, 2021	Expired
US8329680	Formulation	09 Jul, 2021	Expired
US8466139	Formulation	09 Jul, 2021	Expired
US6395767	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	16 Feb, 2021	Expired
US6316460	Pharmaceutical compositions	04 Feb, 2021	Expired
US6774122	Formulation	09 Jan, 2021	Expired
US7456160	Formulation	09 Jan, 2021	Expired
US8329680	Formulation	09 Jan, 2021	Expired
US8466139	Formulation	09 Jan, 2021	Expired
US6414126	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020	Expired
US6936590	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020	Expired
US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	04 Oct, 2020	Expired
US6479065	Process for the preparation of polymer-based sustained release compositions	10 Aug, 2020	Expired
US6316460	Pharmaceutical compositions	04 Aug, 2020	Expired
US6495164	Preparation of injectable suspensions having improved injectability	25 May, 2020	Expired
US6667061	Preparation of injectable suspensions having improved injectability	25 May, 2020	Expired
US5792795	Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids	13 May, 2020	Expired
US5948818	Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids	13 May, 2020	Expired
US6428810	Pharmaceutical formulation comprising omeprazole	03 May, 2020	Expired
US5712298	Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors	27 Jan, 2020	Expired
US6872700	Methods for glucagon suppression	14 Jan, 2020	Expired
US6902744	Exendin agonist formulations and methods of administration thereof	14 Jan, 2020	Expired
US6525060	Triazolo(4,5-d)pyrimidine compounds	02 Dec, 2019	Expired
US7250419	Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition	02 Dec, 2019	Expired
US6403616	Chemical process and pharmaceutical formulation	15 Nov, 2019	Expired
US6428810	Pharmaceutical formulation comprising omeprazole	03 Nov, 2019	Expired
US6598603	Method for treating respiratory diseases	23 Jun, 2019	Expired
US6899099	Method for treating a respiratory disease	23 Jun, 2019	Expired
US7524834	Sterile powders, formulations, and methods for producing the same	11 May, 2019	Expired
US7367333	Inhalation device	11 May, 2019	Expired
US6150380	Crystalline form of omeprazole	10 May, 2019	Expired
US6147103	Omeprazole process and compositions thereof	09 Apr, 2019	Expired
US6166213	Omeprazole process and compositions thereof	09 Apr, 2019	Expired
US6191148	Omerazole process and compositions thereof	09 Apr, 2019	Expired
US6332985	Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions	29 Mar, 2019	Expired
US5686411	Amylin agonist peptides and uses therefor	16 Mar, 2019	Expired
US7897646	Use for budesonide and formoterol	09 Mar, 2019	Expired
US8461211	Use for budesonide and formoterol	09 Mar, 2019	Expired
US6598603	Method for treating respiratory diseases	23 Dec, 2018	Expired
US6899099	Method for treating a respiratory disease	23 Dec, 2018	Expired
US6369085	Form of S-omeprazole	25 Nov, 2018	Expired
US7411070	Form of S-omeprazole	25 Nov, 2018	Expired
US8466175	Form of S-omeprazole	25 Nov, 2018	Expired
US7524834	Sterile powders, formulations, and methods for producing the same	11 Nov, 2018	Expired
US7367333	Inhalation device	11 Nov, 2018	Expired
US6150380	Crystalline form of omeprazole	10 Nov, 2018	Expired
US6147103	Omeprazole process and compositions thereof	09 Oct, 2018	Expired
US6166213	Omeprazole process and compositions thereof	09 Oct, 2018	Expired
US6191148	Omerazole process and compositions thereof	09 Oct, 2018	Expired
US7030152	Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease	02 Oct, 2018	Expired
US7964614	Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease	02 Oct, 2018	Expired
US7897646	Use for budesonide and formoterol	09 Sep, 2018	Expired
US8461211	Use for budesonide and formoterol	09 Sep, 2018	Expired
US6251910	1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists	15 Jul, 2018	Expired
US6369085	Form of S-omeprazole	25 May, 2018	Expired
US7411070	Form of S-omeprazole	25 May, 2018	Expired
US8466175	Form of S-omeprazole	25 May, 2018	Expired
US7030152	Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease	02 Apr, 2018	Expired
US7964614	Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease	02 Apr, 2018	Expired
US6123924	Pressurized aerosol inhalation compositions	26 Mar, 2018	Expired
US6956026	Use of exendins for the reduction of food intake	07 Jan, 2018	Expired
US7741269	Exendins and exendin agonists for weight reduction and obesity	07 Jan, 2018	Expired
US6291445	Low dose budesonide formulations and uses thereof	29 Oct, 2017	Expired
US6686346	Formulation	29 Oct, 2017	Expired
US6986904	Formulation	29 Oct, 2017	Expired
US7297761	Pharmaceutical compositions containing exendins	15 Oct, 2017	Expired
US7521423	Exendin pharmaceutical compositions	15 Oct, 2017	Expired
US6123924	Pressurized aerosol inhalation compositions	26 Sep, 2017	Expired
US6114304	Methods for regulating gastrointestinal motility	05 Sep, 2017	Expired
US5770599	Quinazoline derivatives	05 May, 2017	Expired
US6291445	Low dose budesonide formulations and uses thereof	29 Apr, 2017	Expired
US6686346	Formulation	29 Apr, 2017	Expired
US6986904	Formulation	29 Apr, 2017	Expired
US6858576	Methods for regulating gastrointestinal motility	06 Jan, 2017	Expired
US5424286	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same	01 Dec, 2016	Expired
US5900424	Omeprazole magnesium salt form	04 Nov, 2016	Expired
USRE37314	Pyrimidine derivatives	08 Jul, 2016	Expired
US5900424	Omeprazole magnesium salt form	04 May, 2016	Expired
USRE37314	Pyrimidine derivatives	08 Jan, 2016	Expired
US5817338	Multiple unit tableted dosage form of omeprazole	06 Oct, 2015	Expired
US5814600	Method and composition for treatment of insulin requiring mammals	29 Sep, 2015	Expired
US5714504	Compositions	03 Aug, 2015	Expired
US5753265	Multiple unit pharmaceutical preparation	07 Jun, 2015	Expired
US5690960	Pharmaceutical formulation of omeprazole	25 May, 2015	Expired
US5714504	Compositions	03 Feb, 2015	Expired
US5877192	Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole	27 Nov, 2014	Expired
US6875872	Compounds	27 Nov, 2014	Expired
US5690960	Pharmaceutical formulation of omeprazole	25 Nov, 2014	Expired
US5674860	Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders	07 Oct, 2014	Expired
US5877192	Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole	27 May, 2014	Expired
US6875872	Compounds	27 May, 2014	Expired
US6143771	Compounds	27 May, 2014	Expired
US6608029	Methods for regulating gastrointestinal motility	07 Sep, 2013	Expired
US5466699	Indolyl compounds for treating migraine	14 May, 2013	Expired
US5457105	Quinazoline derivatives useful for treatment of neoplastic disease	19 Jan, 2013	Expired
US5616582	Quinazoline derivatives as anti-proliferative agents	19 Jan, 2013	Expired
US5972919	Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof	17 Dec, 2012	Expired
US5466699	Indolyl compounds for treating migraine	14 Nov, 2012	Expired
US6641800	Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane	23 Sep, 2012	Expired

Latest Legal Activities on Astrazeneca's Drug Patents

Given below is the list of recent legal activities going on the following drug patents of Astrazeneca.

Activity	Date	Patent Number

Expire Patent	16 Feb, 2026	US8628799 (Litigated)
Expire Patent	16 Feb, 2026	US8628799 (Litigated)
Expire Patent	16 Feb, 2026	US8628799 (Litigated)
Expire Patent	02 Feb, 2026	US8618142 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity	22 Jan, 2026	US11406662
Payment of Maintenance Fee, 8th Year, Large Entity	22 Jan, 2026	US10059714
Payment of Maintenance Fee, 8th Year, Large Entity	22 Jan, 2026	US10039766
Payment of Maintenance Fee, 12th Year, Large Entity	21 Jan, 2026	US8808713
Payment of Maintenance Fee, 12th Year, Large Entity	21 Jan, 2026	US8808750
Payment of Maintenance Fee, 12th Year, Large Entity	21 Jan, 2026	US8815258
Payment of Maintenance Fee, 12th Year, Large Entity	21 Jan, 2026	US8802152
Payment of Maintenance Fee, 12th Year, Large Entity	21 Jan, 2026	US8808713
Payment of Maintenance Fee, 12th Year, Large Entity	21 Jan, 2026	US8815258
Recordation of Patent eCertificate of Correction	13 Jan, 2026	US12472194
Patent eCofC Notification	13 Jan, 2026	US12472194

Astrazeneca's Drug Patent Litigations

Astrazeneca's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 11, 2011, against patent number US8859562. The petitioner , challenged the validity of this patent, with Thomas Helleday as the respondent. Click below to track the latest information on how companies are challenging Astrazeneca's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10272083	February, 2023	Institution Denied (07 Aug, 2023)	Acerta Pharma B.V. et al.	Sandoz Inc.
US6774122	August, 2017	Institution Denied (11 Dec, 2017)	AstraZeneca AB	Fresenius Kabi USA,LLC
US8329680	August, 2017	Institution Denied (11 Dec, 2017)	AstraZeneca AB	Fresenius Kabi USA, LLC
US8466139	August, 2017	Institution Denied (11 Dec, 2017)	AstraZeneca AB	FRESENIUS KABI USA, LLC
US6667061	May, 2016	Final Written Decision (28 Nov, 2017)	Alkermes Controlled Therapeutics, Inc. et al.	Luye Pharma Group Ltd. et al.
US6774122	February, 2017	Institution Denied (30 Aug, 2017)	AstraZeneca AB	InnoPharma Licensing LLC et al.
US8329680	February, 2017	Institution Denied (30 Aug, 2017)	AstraZeneca AB	InnoPharma Licensing LLC et al.
US8466139	February, 2017	Institution Denied (30 Aug, 2017)	AstraZeneca AB	InnoPharma Licensing LLC et al.
US7759328	January, 2017	Institution Denied (24 Jul, 2017)	AstraZeneca AB et al.	Complex Innovations, LLC
US6774122	June, 2016	Terminated-Settled (10 Jan, 2017)	AstraZeneca AB	Mylan Pharmaceuticals Inc.
US7456160	June, 2016	Terminated-Settled (10 Jan, 2017)	AstraZeneca AB	Mylan Pharmaceuticals Inc.
US8466139	June, 2016	Terminated-Settled (10 Jan, 2017)	AstraZeneca AB	Mylan Pharmaceuticals Inc.
US8329680	June, 2016	Institution Denied (14 Dec, 2016)	AstraZeneca AB et al.	Mylan Pharmaceuticals Inc. et al.
US6667061	May, 2016	Institution Denied (30 Nov, 2016)	Alkermes Controlled Therapeutics, Inc. et al.	Luye Pharma Group Ltd. et al.
US7297761	December, 2015	Institution Denied (28 Jun, 2016)	Amylin Pharmaceuticals, LLC et al.	Sanofi-Aventis U.S. LLC et al.
US8859562	October, 2011	Decision (25 Mar, 2014)	Thomas Helleday

Astrazeneca Drug Patents' Oppositions Filed in EPO

Astrazeneca drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 25, 2009, by Norton Healthcare Limited. This opposition was filed on patent number EP03703575A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status

EP09812292A	Jan, 2021	Instone, Terry/Read, Howard Graham/Appleyard Lees IP LLP	Granted and Under Opposition
EP16735945A	Jan, 2021	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition
EP08732695A	Dec, 2020	Stada-Arzneimittel Aktiengesellschaft	Granted and Under Opposition
EP08732695A	Dec, 2020	Kraus & Weisert Patentanwälte PartGmbB	Granted and Under Opposition
EP08732695A	Dec, 2020	Gedeon Richter Plc.	Granted and Under Opposition
EP08732695A	Dec, 2020	Galenicum Health S.L.U.	Granted and Under Opposition
EP08732695A	Dec, 2020	Generics [UK] Limited	Granted and Under Opposition
EP08732695A	Dec, 2020	Zentiva, k.s.	Granted and Under Opposition
EP17203302A	Aug, 2020	Generics (U.K.) Limited	Granted and Under Opposition
EP10016112A	Feb, 2020	Generics (UK) Ltd	Granted and Under Opposition
EP10016112A	Jan, 2020	Instone, Terry/Appleyard Lees IP LLP/Read, Howard	Granted and Under Opposition
EP12744254A	Aug, 2019	Sandoz AG	Granted and Under Opposition
EP12744254A	Aug, 2019	Galenicum Health S.L.U.	Granted and Under Opposition
EP12744254A	Aug, 2019	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP10782113A	Apr, 2019	Hoefer & Partner Patentanwälte mbB	Granted and Under Opposition
EP15181545A	Sep, 2018	Generics (U.K.) Limited	Granted and Under Opposition
EP15192658A	Jul, 2018	Generics (U.K.) Limited	Opposition rejected
EP15177189A	Apr, 2018	Generics [UK] Limited (trading as Mylan)	Revoked
EP07794121A	Dec, 2017	Generics [UK] Limited (trading as Mylan)	Revoked
EP07794121A	Dec, 2017	Hexal Biotech GmbH	Revoked
EP07794121A	Dec, 2017	Wittkopp, Alexander	Revoked
EP09740728A	Apr, 2017	Teva Pharmaceutical Industries Ltd	Patent maintained as amended
EP08716685A	Apr, 2017	SHL Group AB	Opposition rejected
EP10179007A	Mar, 2017	Galenicum Health S.L.	Patent maintained as amended
EP05756474A	Jan, 2017	Galenicum Health S.L.	Patent maintained as amended
EP12759801A	Oct, 2016	STADA Arzneimittel AG	Opposition rejected
EP11180259A	Nov, 2015	Teva Pharmaceutical Industries Ltd.	Opposition rejected
EP11180259A	Nov, 2015	PHARMATHEN S.A.	Opposition rejected
EP06801867A	Sep, 2015	Generics [UK] Ltd (trading as Mylan)	Revoked
EP06801867A	Sep, 2015	Teva Pharmaceutical Industries Ltd.	Revoked
EP06801867A	Sep, 2015	COOLEY LLP	Revoked
EP06801867A	Sep, 2015	PENTAFARMA, Sociedade Técnico-Medicinal, SA	Revoked
EP06801867A	Sep, 2015	Glaxo Group Limited	Revoked
EP06801867A	Aug, 2015	PHARMATHEN S.A.	Revoked
EP07784499A	Apr, 2015	LEK Pharmaceuticals d.d.	Patent maintained as amended
EP10173234A	Feb, 2014	Hexal AG	Revoked
EP10173234A	Feb, 2014	Generics [UK] Limited	Revoked
EP03704652A	Dec, 2012	Hexal AG	Revoked
EP04798705A	May, 2012	STRAWMAN LIMITED	Opposition procedure closed
EP04798705A	May, 2012	Adams, Harvey Vaughan John	Opposition procedure closed
EP04743564A	Apr, 2012	Adams, Harvey Vaughan John	Patent maintained as amended
EP04743564A	Apr, 2012	STRAWMAN LIMITED	Patent maintained as amended
EP05702139A	Nov, 2010	Pronova Biopharma Norge AS	Patent maintained as amended
EP05702139A	Nov, 2010	S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a.	Patent maintained as amended
EP05702139A	Nov, 2010	Catalent Pharma Solutions, Inc.	Patent maintained as amended
EP03703575A	Nov, 2009	NORTON HEALTHCARE LIMITED	Revoked

Astrazeneca's Family Patents

Astrazeneca drugs have patent protection in a total of 71 countries. It's US patent count contributes only to 17.8% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Clinical Trials

Recent Clinical Trials by Astrazeneca:

Title	Lead Sponsor	Collaborators	Status	Phases

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.	AstraZeneca	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia	AstraZeneca	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies	AstraZeneca	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE2
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma	AstraZeneca	NA	COMPLETED (Sep 1, 2026)	PHASE3
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features	AstraZeneca	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE1
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE2
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE1
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE1
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF	AstraZeneca	NA	RECRUITING (Sep 1, 2026)	PHASE3
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE1
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients	AstraZeneca	NA	COMPLETED (Aug 1, 2026)	PHASE3
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE1
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension	AstraZeneca	NA	COMPLETED (Aug 1, 2026)	PHASE3
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE1
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Volrustomig Priming Regimens Exploratory Phase II Platform Study	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE1
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE2
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE2
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.	AstraZeneca	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE1
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT	AstraZeneca	NA	RECRUITING (Aug 1, 2026)	PHASE3
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1, PHASE2
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1
Study of AZD2811 + Durvalumab in ES-SCLC	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE2
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE2
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE2
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension	AstraZeneca	NA	COMPLETED (Jul 1, 2026)	PHASE3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma	AstraZeneca	NA	COMPLETED (Jul 1, 2026)	PHASE2
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)	AstraZeneca	NA	RECRUITING (Jul 1, 2026)	PHASE1, PHASE2
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism	AstraZeneca	NA	RECRUITING (Jul 1, 2026)	PHASE3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)	AstraZeneca	NA	RECRUITING (Jul 1, 2026)	PHASE3
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression	AstraZeneca	NA	RECRUITING (Jul 1, 2026)	PHASE1, PHASE2
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer	AstraZeneca	NA	RECRUITING (Jul 1, 2026)	PHASE3
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants	AstraZeneca	NA	COMPLETED (Jul 1, 2026)	PHASE1
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants	AstraZeneca	NA	COMPLETED (Jul 1, 2026)	PHASE1
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	AstraZeneca	NA	RECRUITING (Jul 1, 2026)	PHASE1
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma	AstraZeneca	NA	COMPLETED (Jul 1, 2026)	PHASE1
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE2
A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)	AstraZeneca	NA	NOT YET RECRUITING (Jul 1, 2026)	PHASE3
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05).	AstraZeneca	NA	COMPLETED (Jun 1, 2026)	PHASE2, PHASE3
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07).	AstraZeneca	NA	COMPLETED (Jun 1, 2026)	PHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jun 1, 2026)	PHASE3
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer	AstraZeneca	NA	COMPLETED (Jun 1, 2026)	PHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jun 1, 2026)	PHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jun 1, 2026)	PHASE3
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)	AstraZeneca	NA	COMPLETED (Jun 1, 2026)	PHASE3
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jun 1, 2026)	PHASE3
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL	AstraZeneca	NA	RECRUITING (Jun 1, 2026)	PHASE3
A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.	AstraZeneca	NA	NOT YET RECRUITING (Jun 1, 2026)	PHASE3
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC	AstraZeneca	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE1
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC	AstraZeneca	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin	AstraZeneca	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE3
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)	AstraZeneca	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE3
Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)	AstraZeneca	NA	COMPLETED (May 1, 2026)	PHASE2, PHASE3
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	AstraZeneca	NA	RECRUITING (May 1, 2026)	PHASE2
Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.	AstraZeneca	NA	COMPLETED (May 1, 2026)	PHASE1
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.	AstraZeneca	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	AstraZeneca	NA	RECRUITING (May 1, 2026)	PHASE3
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma	AstraZeneca	NA	COMPLETED (May 1, 2026)	PHASE3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus	AstraZeneca	NA	RECRUITING (May 1, 2026)	PHASE3
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).	AstraZeneca	NA	NOT YET RECRUITING (May 1, 2026)	PHASE3
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer	AstraZeneca	NA	COMPLETED (Apr 1, 2026)	PHASE3
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies	AstraZeneca	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE1, PHASE2
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer	AstraZeneca	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations	AstraZeneca	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE3
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food	AstraZeneca	NA	COMPLETED (Apr 1, 2026)	PHASE1
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors	AstraZeneca	NA	RECRUITING (Mar 1, 2026)	PHASE2
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone	AstraZeneca	NA	COMPLETED (Jul, 2024)	PHASE4
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece	AstraZeneca	NA	ACTIVE NOT RECRUITING (Jul, 2024)
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia	AstraZeneca	NA	TERMINATED (Jun, 2024)	PHASE3
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China	AstraZeneca	NA	COMPLETED (Jun, 2024)
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.	AstraZeneca	NA	COMPLETED (Oct, 2022)	PHASE3
ZS Ph2/3 Dose-response Study in Japan	AstraZeneca	NA	COMPLETED (Feb, 2019)	PHASE2, PHASE3
A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)	AstraZeneca	NA	COMPLETED (Dec, 2017)	PHASE1

Astrazeneca Drug List

Given below is the complete list of Astrazeneca's drugs and the patents protecting them.

1. Airsupra

Airsupra is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9415009	Compositions, methods and systems for respiratory delivery of two or more active agents	28 May, 2030 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Airsupra's drug page

2. Baxfendy

Baxfendy is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9353081	Bicyclic Dihydroquinoline-2-One Derivatives	04 Feb, 2033 (6 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Baxfendy's drug page

3. Bevespi Aerosphere

Bevespi Aerosphere is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8815258	Compositions, methods and systems for respiratory delivery of two or more active agents	17 Mar, 2031 (4 years from now)	Active
US10716753	Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems	28 May, 2030 (3 years from now)	Active
US8324266	Compositions, methods and systems for respiratory delivery of two or more active agents	28 May, 2030 (3 years from now)	Active
US8703806	Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents	28 May, 2030 (3 years from now)	Active
US8808713	Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems	28 May, 2030 (3 years from now)	Active
US9415009	Compositions, methods and systems for respiratory delivery of two or more active agents	28 May, 2030 (3 years from now)	Active
US9463161	Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems	28 May, 2030 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bevespi Aerosphere's drug page

4. Breztri Aerosphere

Breztri Aerosphere is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11331442	Drug delivery systems and related methods	05 Oct, 2038 (12 years from now)	Active
US11833292	Drug delivery systems and related methods	05 Oct, 2038 (12 years from now)	Active
US8815258	Compositions, methods and systems for respiratory delivery of two or more active agents	17 Mar, 2031 (4 years from now)	Active
US10716753	Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems	28 May, 2030 (3 years from now)	Active
US8324266	Compositions, methods and systems for respiratory delivery of two or more active agents	28 May, 2030 (3 years from now)	Active
US8703806	Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents	28 May, 2030 (3 years from now)	Active
US8808713	Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems	28 May, 2030 (3 years from now)	Active
US9415009	Compositions, methods and systems for respiratory delivery of two or more active agents	28 May, 2030 (3 years from now)	Active
US9463161	Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems	28 May, 2030 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Breztri Aerosphere's drug page

5. Brilinta

Brilinta is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10300065 (Pediatric)	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction	27 Jul, 2036 (9 years from now)	Active
US10300065	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction	27 Jan, 2036 (9 years from now)	Active
US8425934 (Pediatric)	Pharmaceutical compositions	17 Oct, 2030 (4 years from now)	Active
US8425934	Pharmaceutical compositions	17 Apr, 2030 (3 years from now)	Active
USRE46276 (Pediatric)	Triazolo(4,5-D)pyrimidine compounds	30 Apr, 2025 (1 year, 5 months ago)	Expired
USRE46276	Triazolo(4,5-D)pyrimidine compounds	30 Oct, 2024 (1 year, 11 months ago)	Expired
US7265124	Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound	09 Jul, 2021 (5 years ago)	Expired
US6525060	Triazolo(4,5-d)pyrimidine compounds	02 Dec, 2019 (6 years ago)	Expired
US7250419	Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition	02 Dec, 2019 (6 years ago)	Expired
US6251910	1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists	15 Jul, 2018 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brilinta's drug page

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

6. Bydureon

Bydureon is protected by 46 patents, out of which 32 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8685934	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	26 May, 2030 (3 years from now)	Active
US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Dec, 2029 (3 years from now)	Active
US8361972 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US7851502	Pharmaceutical formulations containing an SGLT2 inhibitor	19 Aug, 2028 (1 year, 10 months from now)	Active
US8439864	Device for administering fluid from a multi-chamber ampoule in incremental steps	25 Mar, 2028 (1 year, 5 months from now)	Active
US8221786	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8361972	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8716251	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8216180	Administering apparatus with functional drive element	12 Jan, 2028 (1 year, 3 months from now)	Active
US8501698 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Dec, 2027 (1 year, 2 months from now)	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Jun, 2027 (8 months from now)	Active
US8329648 (Pediatric)	Methods for treating diabetes and reducing body weight	18 Feb, 2027 (4 months from now)	Active
US8906851 (Pediatric)	Method for treating diabetes	18 Feb, 2027 (4 months from now)	Active
US9884092 (Pediatric)	Methods for treating diabetes and reducing body weight	18 Feb, 2027 (4 months from now)	Active
US8329648	Methods for treating diabetes and reducing body weight	18 Aug, 2026 (a month ago)	Expired
US8906851	Method for treating diabetes	18 Aug, 2026 (a month ago)	Expired
US9884092	Methods for treating diabetes and reducing body weight	18 Aug, 2026 (a month ago)	Expired
US6515117 (Pediatric)	C-aryl glucoside SGLT2 inhibitors and method	04 Apr, 2026 (5 months ago)	Expired
US7456254 (Pediatric)	Polymer-based sustained release device	30 Dec, 2025 (9 months ago)	Expired
US7612176 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US8431685 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US8461105 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2025 (11 months ago)	Expired
US7456254	Polymer-based sustained release device	30 Jun, 2025 (1 year, 3 months ago)	Expired
US7612176	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US8431685	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US8461105	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US7563871 (Pediatric)	Polymer-based sustained release device	15 Oct, 2024 (1 year, 11 months ago)	Expired
US9238076 (Pediatric)	Polymer-based sustained release device	15 Oct, 2024 (1 year, 11 months ago)	Expired
US7563871	Polymer-based sustained release device	15 Apr, 2024 (2 years ago)	Expired
US9238076	Polymer-based sustained release device	15 Apr, 2024 (2 years ago)	Expired
US6824822 (Pediatric)	Residual solvent extraction method and microparticles produced thereby	09 Apr, 2023 (3 years ago)	Expired
US6824822	Residual solvent extraction method and microparticles produced thereby	09 Oct, 2022 (3 years ago)	Expired
US7223440 (Pediatric)	Residual solvent extraction method and microparticles produced thereby	03 Mar, 2022 (4 years ago)	Expired
US7223440	Residual solvent extraction method and microparticles produced thereby	31 Aug, 2021 (5 years ago)	Expired
US6414126	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US6936590	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	04 Oct, 2020 (6 years ago)	Expired
US6479065	Process for the preparation of polymer-based sustained release compositions	10 Aug, 2020 (6 years ago)	Expired
US6495164	Preparation of injectable suspensions having improved injectability	25 May, 2020 (6 years ago)	Expired
US6667061	Preparation of injectable suspensions having improved injectability	25 May, 2020 (6 years ago)	Expired
US6872700	Methods for glucagon suppression	14 Jan, 2020 (6 years ago)	Expired
US6956026	Use of exendins for the reduction of food intake	07 Jan, 2018 (8 years ago)	Expired
US7741269	Exendins and exendin agonists for weight reduction and obesity	07 Jan, 2018 (8 years ago)	Expired
US6858576	Methods for regulating gastrointestinal motility	06 Jan, 2017 (9 years ago)	Expired
US5424286	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same	01 Dec, 2016 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon's drug page

7. Bydureon Bcise

Bydureon Bcise is protected by 38 patents, out of which 29 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8895033 (Pediatric)	Sustained release formulations using non-aqueous carriers	04 Apr, 2031 (4 years from now)	Active
US8895033	Sustained release formulations using non-aqueous carriers	04 Oct, 2030 (4 years from now)	Active
US8361972 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US8361972	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8501698 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Dec, 2027 (1 year, 2 months from now)	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Jun, 2027 (8 months from now)	Active
US8329648 (Pediatric)	Methods for treating diabetes and reducing body weight	18 Feb, 2027 (4 months from now)	Active
US8906851 (Pediatric)	Method for treating diabetes	18 Feb, 2027 (4 months from now)	Active
US9884092 (Pediatric)	Methods for treating diabetes and reducing body weight	18 Feb, 2027 (4 months from now)	Active
US8329648	Methods for treating diabetes and reducing body weight	18 Aug, 2026 (a month ago)	Expired
US8906851	Method for treating diabetes	18 Aug, 2026 (a month ago)	Expired
US9884092	Methods for treating diabetes and reducing body weight	18 Aug, 2026 (a month ago)	Expired
US6515117 (Pediatric)	C-aryl glucoside SGLT2 inhibitors and method	04 Apr, 2026 (5 months ago)	Expired
US7456254 (Pediatric)	Polymer-based sustained release device	30 Dec, 2025 (9 months ago)	Expired
US7612176 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US8431685 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US8461105 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2025 (11 months ago)	Expired
US7456254	Polymer-based sustained release device	30 Jun, 2025 (1 year, 3 months ago)	Expired
US7612176	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US8431685	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US8461105	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US7563871 (Pediatric)	Polymer-based sustained release device	15 Oct, 2024 (1 year, 11 months ago)	Expired
US9238076 (Pediatric)	Polymer-based sustained release device	15 Oct, 2024 (1 year, 11 months ago)	Expired
US7563871	Polymer-based sustained release device	15 Apr, 2024 (2 years ago)	Expired
US9238076	Polymer-based sustained release device	15 Apr, 2024 (2 years ago)	Expired
US6824822 (Pediatric)	Residual solvent extraction method and microparticles produced thereby	09 Apr, 2023 (3 years ago)	Expired
US6824822	Residual solvent extraction method and microparticles produced thereby	09 Oct, 2022 (3 years ago)	Expired
US7223440 (Pediatric)	Residual solvent extraction method and microparticles produced thereby	03 Mar, 2022 (4 years ago)	Expired
US7223440	Residual solvent extraction method and microparticles produced thereby	31 Aug, 2021 (5 years ago)	Expired
US6414126	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US6936590	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	04 Oct, 2020 (6 years ago)	Expired
US6479065	Process for the preparation of polymer-based sustained release compositions	10 Aug, 2020 (6 years ago)	Expired
US6667061	Preparation of injectable suspensions having improved injectability	25 May, 2020 (6 years ago)	Expired
US6872700	Methods for glucagon suppression	14 Jan, 2020 (6 years ago)	Expired
US6956026	Use of exendins for the reduction of food intake	07 Jan, 2018 (8 years ago)	Expired
US7741269	Exendins and exendin agonists for weight reduction and obesity	07 Jan, 2018 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon Bcise's drug page

8. Bydureon Pen

Bydureon Pen is protected by 60 patents, out of which 32 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8721615 (Pediatric)	Ampoule comprising an ampoule holder	18 Jul, 2030 (3 years from now)	Active
US8998876 (Pediatric)	Ampoule comprising an ampoule holder	07 Jul, 2030 (3 years from now)	Active
US8685934	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	26 May, 2030 (3 years from now)	Active
US8721615	Ampoule comprising an ampoule holder	18 Jan, 2030 (3 years from now)	Active
US8998876	Ampoule comprising an ampoule holder	07 Jan, 2030 (3 years from now)	Active
US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Dec, 2029 (3 years from now)	Active
US8690837 (Pediatric)	Mixing device for a two-chamber ampoule	19 Nov, 2029 (3 years from now)	Active
US8827963 (Pediatric)	Administering device with holding mechanism	04 Aug, 2029 (2 years from now)	Active
US8690837	Mixing device for a two-chamber ampoule	19 May, 2029 (2 years from now)	Active
US8827963	Administering device with holding mechanism	04 Feb, 2029 (2 years from now)	Active
US8439864 (Pediatric)	Device for administering fluid from a multi-chamber ampoule in incremental steps	25 Sep, 2028 (1 year, 11 months from now)	Active
US9320853 (Pediatric)	Method for administering a fluid active substance from a multi-chamber ampoule	25 Sep, 2028 (1 year, 11 months from now)	Active
US8361972 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US7851502	Pharmaceutical formulations containing an SGLT2 inhibitor	19 Aug, 2028 (1 year, 10 months from now)	Active
US8216180 (Pediatric)	Administering apparatus with functional drive element	12 Jul, 2028 (1 year, 9 months from now)	Active
US8758292 (Pediatric)	Administering apparatus with functional drive element	12 May, 2028 (1 year, 7 months from now)	Active
US8439864	Device for administering fluid from a multi-chamber ampoule in incremental steps	25 Mar, 2028 (1 year, 5 months from now)	Active
US9320853	Method for administering a fluid active substance from a multi-chamber ampoule	25 Mar, 2028 (1 year, 5 months from now)	Active
US8221786	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8361972	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8716251	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8216180	Administering apparatus with functional drive element	12 Jan, 2028 (1 year, 3 months from now)	Active
US8501698 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Dec, 2027 (1 year, 2 months from now)	Active
US8758292	Administering apparatus with functional drive element	12 Nov, 2027 (1 year, 1 month from now)	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Jun, 2027 (8 months from now)	Active
US8329648 (Pediatric)	Methods for treating diabetes and reducing body weight	18 Feb, 2027 (4 months from now)	Active
US8906851 (Pediatric)	Method for treating diabetes	18 Feb, 2027 (4 months from now)	Active
US9884092 (Pediatric)	Methods for treating diabetes and reducing body weight	18 Feb, 2027 (4 months from now)	Active
US8329648	Methods for treating diabetes and reducing body weight	18 Aug, 2026 (a month ago)	Expired
US8906851	Method for treating diabetes	18 Aug, 2026 (a month ago)	Expired
US9884092	Methods for treating diabetes and reducing body weight	18 Aug, 2026 (a month ago)	Expired
US6515117 (Pediatric)	C-aryl glucoside SGLT2 inhibitors and method	04 Apr, 2026 (5 months ago)	Expired
US7456254 (Pediatric)	Polymer-based sustained release device	30 Dec, 2025 (9 months ago)	Expired
US7612176 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US8431685 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US8461105 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2025 (11 months ago)	Expired
US7456254	Polymer-based sustained release device	30 Jun, 2025 (1 year, 3 months ago)	Expired
US7612176	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US8431685	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US8461105	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US7563871 (Pediatric)	Polymer-based sustained release device	15 Oct, 2024 (1 year, 11 months ago)	Expired
US9238076 (Pediatric)	Polymer-based sustained release device	15 Oct, 2024 (1 year, 11 months ago)	Expired
US7563871	Polymer-based sustained release device	15 Apr, 2024 (2 years ago)	Expired
US9238076	Polymer-based sustained release device	15 Apr, 2024 (2 years ago)	Expired
US6824822 (Pediatric)	Residual solvent extraction method and microparticles produced thereby	09 Apr, 2023 (3 years ago)	Expired
US6824822	Residual solvent extraction method and microparticles produced thereby	09 Oct, 2022 (3 years ago)	Expired
US7223440 (Pediatric)	Residual solvent extraction method and microparticles produced thereby	03 Mar, 2022 (4 years ago)	Expired
US7223440	Residual solvent extraction method and microparticles produced thereby	31 Aug, 2021 (5 years ago)	Expired
US6414126	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US6936590	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	04 Oct, 2020 (6 years ago)	Expired
US6479065	Process for the preparation of polymer-based sustained release compositions	10 Aug, 2020 (6 years ago)	Expired
US6495164	Preparation of injectable suspensions having improved injectability	25 May, 2020 (6 years ago)	Expired
US6667061	Preparation of injectable suspensions having improved injectability	25 May, 2020 (6 years ago)	Expired
US6872700	Methods for glucagon suppression	14 Jan, 2020 (6 years ago)	Expired
US6956026	Use of exendins for the reduction of food intake	07 Jan, 2018 (8 years ago)	Expired
US7741269	Exendins and exendin agonists for weight reduction and obesity	07 Jan, 2018 (8 years ago)	Expired
US6858576	Methods for regulating gastrointestinal motility	06 Jan, 2017 (9 years ago)	Expired
US5424286	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same	01 Dec, 2016 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon Pen's drug page

9. Byetta

Byetta is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6872700	Methods for glucagon suppression	14 Jan, 2020 (6 years ago)	Expired
US6902744	Exendin agonist formulations and methods of administration thereof	14 Jan, 2020 (6 years ago)	Expired
US6956026	Use of exendins for the reduction of food intake	07 Jan, 2018 (8 years ago)	Expired
US7741269	Exendins and exendin agonists for weight reduction and obesity	07 Jan, 2018 (8 years ago)	Expired
US7297761	Pharmaceutical compositions containing exendins	15 Oct, 2017 (8 years ago)	Expired
US7521423	Exendin pharmaceutical compositions	15 Oct, 2017 (8 years ago)	Expired
US6858576	Methods for regulating gastrointestinal motility	06 Jan, 2017 (9 years ago)	Expired
US5424286	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same	01 Dec, 2016 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Byetta's drug page

10. Calquence

Calquence is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10167291	Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide	01 Jul, 2036 (9 years from now)	Active
US11059829	Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate	01 Jul, 2036 (9 years from now)	Active
US9796721	Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide	01 Jul, 2036 (9 years from now)	Active
US11166951	Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor	11 Aug, 2035 (8 years from now)	Active
US10272083	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	21 Jan, 2035 (8 years from now)	Active
US11771696	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor	21 Jan, 2035 (8 years from now)	Active
US10239883	4-imidazopyridazin-1-yl-benzamides as BTK inhibitors	11 Jul, 2032 (5 years from now)	Active
US9290504	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors	11 Jul, 2032 (5 years from now)	Active
US9758524	4-imidazopyridazin-1-yl-benzamides as Btk inhibitors	11 Jul, 2032 (5 years from now)	Active
US7459554	Imidazopyrazine tyrosine kinase inhibitors	24 Nov, 2026 (a month from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Calquence's drug page

11. Crestor

Crestor is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6858618 (Pediatric)	Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia	17 Jun, 2022 (4 years ago)	Expired
US6858618	Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia	17 Dec, 2021 (4 years ago)	Expired
US6316460 (Pediatric)	Pharmaceutical compositions	04 Feb, 2021 (5 years ago)	Expired
US6316460	Pharmaceutical compositions	04 Aug, 2020 (6 years ago)	Expired
US7030152 (Pediatric)	Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease	02 Oct, 2018 (8 years ago)	Expired
US7964614 (Pediatric)	Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease	02 Oct, 2018 (8 years ago)	Expired
US7030152	Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease	02 Apr, 2018 (8 years ago)	Expired
US7964614	Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease	02 Apr, 2018 (8 years ago)	Expired
USRE37314 (Pediatric)	Pyrimidine derivatives	08 Jul, 2016 (10 years ago)	Expired
USRE37314	Pyrimidine derivatives	08 Jan, 2016 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crestor's drug page

12. Daliresp

Daliresp is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8536206	Process for the preparation of roflumilast	08 Mar, 2024 (2 years ago)	Expired
US8604064	Process for the preparation of roflumilast	08 Mar, 2024 (2 years ago)	Expired
US8618142	Process for the preparation of roflumilast	08 Mar, 2024 (2 years ago)	Expired
US8431154	Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient	19 Feb, 2023 (3 years ago)	Expired
US9468598	Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient	19 Feb, 2023 (3 years ago)	Expired
US5712298	Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors	27 Jan, 2020 (6 years ago)	Expired
US5712298	Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors	27 Jan, 2015 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daliresp's drug page

13. Epanova

Epanova is protected by 9 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10117844	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	04 Jan, 2033 (6 years from now)	Active
US9050308	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	04 Jan, 2033 (6 years from now)	Active
US9050309	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	04 Jan, 2033 (6 years from now)	Active
US7960370	Type A gelatin capsule containing PUFA in free acid form	20 Dec, 2026 (2 months from now)	Active
US8383678	Type a gelatin capsule containing PUFA in free acid form	07 Feb, 2025 (1 year, 7 months ago)	Expired
US9012501	Type A gelatin capsule containing PUFA in free acid form	07 Feb, 2025 (1 year, 7 months ago)	Expired
US9132112	Type A gelatin capsule containing PUFA in free acid form	07 Feb, 2025 (1 year, 7 months ago)	Expired
US5792795	Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids	13 May, 2020 (6 years ago)	Expired
US5948818	Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids	13 May, 2020 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epanova's drug page

14. Farxiga

Farxiga is protected by 44 patents, out of which 14 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12213988 (Pediatric)	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	01 Oct, 2041 (15 years from now)	Active
US12409186 (Pediatric)	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	01 Oct, 2041 (15 years from now)	Active
US12213988	Methods of treating chronic kidney disease with dapagliflozin	01 Apr, 2041 (14 years from now)	Active
US12409186	Methods Of Treating Chronic Kidney Disease With Dapagliflozin	01 Apr, 2041 (14 years from now)	Active
US10973836 (Pediatric)	Methods of treating heart failure with reduced ejection fraction	09 Sep, 2040 (13 years from now)	Active
US11903955 (Pediatric)	Methods of treating heart failure with reduced ejection fraction	09 Sep, 2040 (13 years from now)	Active
US10973836	Methods of treating heart failure with reduced ejection fraction	09 Mar, 2040 (13 years from now)	Active
US11903955	Methods of treating heart failure with reduced ejection fraction	09 Mar, 2040 (13 years from now)	Active
US11826376 (Pediatric)	Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same	18 Jan, 2040 (13 years from now)	Active
US12472194 (Pediatric)	Methods Of Treating Heart Failure With Preserved Ejection Fraction Employing Dapagliflozin And Compositions Comprising The Same	18 Jan, 2040 (13 years from now)	Active
US11826376	Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same	18 Jul, 2039 (12 years from now)	Active
US12472194	Methods Of Treating Heart Failure With Preserved Ejection Fraction Employing Dapagliflozin And Compositions Comprising The Same	18 Jul, 2039 (12 years from now)	Active
US8685934 (Pediatric)	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	26 Nov, 2030 (4 years from now)	Active
US8721615 (Pediatric)	Ampoule comprising an ampoule holder	18 Jul, 2030 (3 years from now)	Active
US7919598 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Jun, 2030 (3 years from now)	Active
US8685934	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	26 May, 2030 (3 years from now)	Active
US8721615	Ampoule comprising an ampoule holder	18 Jan, 2030 (3 years from now)	Active
US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Dec, 2029 (3 years from now)	Active
US7851502 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	19 Feb, 2029 (2 years from now)	Active
US8221786 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US8361972 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US8716251 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US7851502	Pharmaceutical formulations containing an SGLT2 inhibitor	19 Aug, 2028 (1 year, 10 months from now)	Active
US8221786	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8361972	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8716251	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8501698 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Dec, 2027 (1 year, 2 months from now)	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Jun, 2027 (8 months from now)	Active
US8329648 (Pediatric)	Methods for treating diabetes and reducing body weight	18 Feb, 2027 (4 months from now)	Active
US8906851 (Pediatric)	Method for treating diabetes	18 Feb, 2027 (4 months from now)	Active
US8329648	Methods for treating diabetes and reducing body weight	18 Aug, 2026 (a month ago)	Expired
US8906851	Method for treating diabetes	18 Aug, 2026 (a month ago)	Expired
US6515117 (Pediatric)	C-aryl glucoside SGLT2 inhibitors and method	04 Apr, 2026 (5 months ago)	Expired
US7456254 (Pediatric)	Polymer-based sustained release device	30 Dec, 2025 (9 months ago)	Expired
US8431685 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US8461105 (Pediatric)	Polymer-based sustained release device	13 Oct, 2025 (11 months ago)	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2025 (11 months ago)	Expired
US7456254	Polymer-based sustained release device	30 Jun, 2025 (1 year, 3 months ago)	Expired
US8431685	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US8461105	Polymer-based sustained release device	13 Apr, 2025 (1 year, 5 months ago)	Expired
US9238076	Polymer-based sustained release device	15 Apr, 2024 (2 years ago)	Expired
US6414126	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US6936590	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	04 Oct, 2020 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Farxiga's drug page

15. Faslodex

Faslodex is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6774122 (Pediatric)	Formulation	09 Jul, 2021 (5 years ago)	Expired
US7456160 (Pediatric)	Formulation	09 Jul, 2021 (5 years ago)	Expired
US8329680 (Pediatric)	Formulation	09 Jul, 2021 (5 years ago)	Expired
US8466139 (Pediatric)	Formulation	09 Jul, 2021 (5 years ago)	Expired
US6774122	Formulation	09 Jan, 2021 (5 years ago)	Expired
US7456160	Formulation	09 Jan, 2021 (5 years ago)	Expired
US8329680	Formulation	09 Jan, 2021 (5 years ago)	Expired
US8466139	Formulation	09 Jan, 2021 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Faslodex's drug page

16. Iressa

Iressa is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5770599	Quinazoline derivatives	05 May, 2017 (9 years ago)	Expired
US5457105	Quinazoline derivatives useful for treatment of neoplastic disease	19 Jan, 2013 (13 years ago)	Expired
US5616582	Quinazoline derivatives as anti-proliferative agents	19 Jan, 2013 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Iressa's drug page

17. Kombiglyze Xr

Kombiglyze Xr is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8628799	Coated tablet formulation and method	13 Jul, 2025 (1 year, 2 months ago)	Expired
US9339472	Coated tablet formulation and method	13 Jul, 2025 (1 year, 2 months ago)	Expired
USRE44186	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	31 Jul, 2023 (3 years ago)	Expired
US6395767	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	16 Feb, 2021 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kombiglyze Xr's drug page

18. Koselugo

Koselugo is protected by 8 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11813246	Pharmaceutical composition	26 Mar, 2029 (2 years from now)	Active
US12220403	Pharmaceutical composition	26 Mar, 2029 (2 years from now)	Active
US12318367	Pharmaceutical composition	26 Mar, 2029 (2 years from now)	Active
US12364684	Pharmaceutical Composition	26 Mar, 2029 (2 years from now)	Active
US7425637	N3 alkylated benzimidazole derivatives as MEK inhibitors	13 Mar, 2028 (1 year, 5 months from now)	Active
US9156795	Hydrogen sulfate salt	12 Dec, 2026 (2 months from now)	Active
US9562017	Hydrogen sulfate salt	12 Dec, 2026 (2 months from now)	Active
US8178693	N3 alkylated benzimidazole derivatives as MEK inhibitors	13 Mar, 2026 (6 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Koselugo's drug page

19. Lokelma

Lokelma is protected by 15 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10300087	Extended use zirconium silicate compositions and methods of use thereof	14 Oct, 2035 (9 years from now)	Active
US11738044	Extended use zirconium silicate compositions and methods of use thereof	14 Oct, 2035 (9 years from now)	Active
US9592253	Extended use zirconium silicate compositions and methods of use thereof	14 Oct, 2035 (9 years from now)	Active
US10695365	Microporous zirconium silicate for the treatment of hyperkalemia	22 Oct, 2033 (7 years from now)	Active
US8877255	Microporous zirconium silicate for the treatment of hyperkalemia	22 Oct, 2033 (7 years from now)	Active
US9913860	Microporous zirconium silicate for the treatment of hyperkalemia	22 Oct, 2033 (7 years from now)	Active
US8802152	Microporous zirconium silicate for the treatment of hyperkalemia	19 Apr, 2032 (5 years from now)	Active
US10335432	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032 (5 years from now)	Active
US10398730	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032 (5 years from now)	Active
US10413569	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032 (5 years from now)	Active
US11406662	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032 (5 years from now)	Active
US8808750	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032 (5 years from now)	Active
US9844567	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032 (5 years from now)	Active
US9861658	Microporous zirconium silicate for the treatment of hyperkalemia	10 Feb, 2032 (5 years from now)	Active
US6332985	Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions	29 Mar, 2019 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lokelma's drug page

20. Lynparza

Lynparza is protected by 18 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11970530	Methods of treating homologous recombination deficient cancer	25 Oct, 2041 (15 years from now)	Active
US8859562	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	04 Aug, 2031 (4 years from now)	Active
US8475842	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	31 Dec, 2029 (3 years from now)	Active
US11633396	Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one	07 Oct, 2029 (3 years from now)	Active
US11975001	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	07 Oct, 2029 (3 years from now)	Active
US12048695	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	07 Oct, 2029 (3 years from now)	Active
US12144810	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	07 Oct, 2029 (3 years from now)	Active
US12178816	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	07 Oct, 2029 (3 years from now)	Active
US8247416	Phthalazinone derivative	24 Sep, 2028 (1 year, 11 months from now)	Active
US7449464	Phthalazinone derivatives	08 Sep, 2027 (11 months from now)	Active
US8071579	DNA damage repair inhibitors for the treatment of cancer	12 Aug, 2027 (10 months from now)	Active
US8143241	DNA damage repair inhibitors for treatment of cancer	12 Aug, 2027 (10 months from now)	Active
US7449464	Phthalazinone derivatives	11 Oct, 2024 (1 year, 11 months ago)	Expired
US7981889	Phthalazinone derivatives	11 Oct, 2024 (1 year, 11 months ago)	Expired
US8912187	Phthalazinone derivatives	12 Mar, 2024 (2 years ago)	Expired
US9169235	Phthalazinone derivatives	12 Mar, 2024 (2 years ago)	Expired
US9566276	Phthalazinone derivatives	12 Mar, 2024 (2 years ago)	Expired
US7151102	Phthalazinone derivatives	29 Apr, 2022 (4 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lynparza's drug page

21. Nexium

Nexium is protected by 24 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6428810 (Pediatric)	Pharmaceutical formulation comprising omeprazole	03 May, 2020 (6 years ago)	Expired
US6428810	Pharmaceutical formulation comprising omeprazole	03 Nov, 2019 (6 years ago)	Expired
US6147103 (Pediatric)	Omeprazole process and compositions thereof	09 Apr, 2019 (7 years ago)	Expired
US6166213 (Pediatric)	Omeprazole process and compositions thereof	09 Apr, 2019 (7 years ago)	Expired
US6191148 (Pediatric)	Omerazole process and compositions thereof	09 Apr, 2019 (7 years ago)	Expired
US6369085 (Pediatric)	Form of S-omeprazole	25 Nov, 2018 (7 years ago)	Expired
US7411070 (Pediatric)	Form of S-omeprazole	25 Nov, 2018 (7 years ago)	Expired
US8466175 (Pediatric)	Form of S-omeprazole	25 Nov, 2018 (7 years ago)	Expired
US6147103	Omeprazole process and compositions thereof	09 Oct, 2018 (7 years ago)	Expired
US6166213	Omeprazole process and compositions thereof	09 Oct, 2018 (7 years ago)	Expired
US6191148	Omerazole process and compositions thereof	09 Oct, 2018 (7 years ago)	Expired
US6369085	Form of S-omeprazole	25 May, 2018 (8 years ago)	Expired
US7411070	Form of S-omeprazole	25 May, 2018 (8 years ago)	Expired
US8466175	Form of S-omeprazole	25 May, 2018 (8 years ago)	Expired
US5900424 (Pediatric)	Omeprazole magnesium salt form	04 Nov, 2016 (9 years ago)	Expired
US5900424	Omeprazole magnesium salt form	04 May, 2016 (10 years ago)	Expired
US5714504 (Pediatric)	Compositions	03 Aug, 2015 (11 years ago)	Expired
US5690960 (Pediatric)	Pharmaceutical formulation of omeprazole	25 May, 2015 (11 years ago)	Expired
US5714504	Compositions	03 Feb, 2015 (11 years ago)	Expired
US5877192 (Pediatric)	Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole	27 Nov, 2014 (11 years ago)	Expired
US6875872 (Pediatric)	Compounds	27 Nov, 2014 (11 years ago)	Expired
US5690960	Pharmaceutical formulation of omeprazole	25 Nov, 2014 (11 years ago)	Expired
US5877192	Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole	27 May, 2014 (12 years ago)	Expired
US6875872	Compounds	27 May, 2014 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexium's drug page

22. Nexium 24hr

Nexium 24hr is protected by 18 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6428810 (Pediatric)	Pharmaceutical formulation comprising omeprazole	03 May, 2020 (6 years ago)	Expired
US6428810	Pharmaceutical formulation comprising omeprazole	03 Nov, 2019 (6 years ago)	Expired
US6369085 (Pediatric)	Form of S-omeprazole	25 Nov, 2018 (7 years ago)	Expired
US7411070 (Pediatric)	Form of S-omeprazole	25 Nov, 2018 (7 years ago)	Expired
US7411070 (Pediatric)	Form of S-omeprazole	18 Nov, 2018 (7 years ago)	Expired
US6369085	Form of S-omeprazole	25 May, 2018 (8 years ago)	Expired
US7411070	Form of S-omeprazole	25 May, 2018 (8 years ago)	Expired
US7411070	Form of S-omeprazole	18 May, 2018 (8 years ago)	Expired
US5900424 (Pediatric)	Omeprazole magnesium salt form	04 Nov, 2016 (9 years ago)	Expired
US5900424	Omeprazole magnesium salt form	04 May, 2016 (10 years ago)	Expired
US5714504 (Pediatric)	Compositions	03 Aug, 2015 (11 years ago)	Expired
US5690960 (Pediatric)	Pharmaceutical formulation of omeprazole	25 May, 2015 (11 years ago)	Expired
US5714504	Compositions	03 Feb, 2015 (11 years ago)	Expired
US5877192 (Pediatric)	Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole	27 Nov, 2014 (11 years ago)	Expired
US6875872 (Pediatric)	Compounds	27 Nov, 2014 (11 years ago)	Expired
US5690960	Pharmaceutical formulation of omeprazole	25 Nov, 2014 (11 years ago)	Expired
US5877192	Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole	27 May, 2014 (12 years ago)	Expired
US6875872	Compounds	27 May, 2014 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexium 24hr's drug page

23. Nexium Iv

Nexium Iv is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5877192 (Pediatric)	Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole	27 Nov, 2014 (11 years ago)	Expired
US5877192	Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole	27 May, 2014 (12 years ago)	Expired
US6143771	Compounds	27 May, 2014 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexium Iv's drug page

24. Onglyza

Onglyza is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7951400	Coated tablet formulation and method	30 Nov, 2028 (2 years from now)	Active
USRE44186	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	31 Jul, 2023 (3 years ago)	Expired
US6395767	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	16 Feb, 2021 (5 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onglyza's drug page

25. Prilosec

Prilosec is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6150380 (Pediatric)	Crystalline form of omeprazole	10 May, 2019 (7 years ago)	Expired
US6147103 (Pediatric)	Omeprazole process and compositions thereof	09 Apr, 2019 (7 years ago)	Expired
US6166213 (Pediatric)	Omeprazole process and compositions thereof	09 Apr, 2019 (7 years ago)	Expired
US6191148 (Pediatric)	Omerazole process and compositions thereof	09 Apr, 2019 (7 years ago)	Expired
US6150380	Crystalline form of omeprazole	10 Nov, 2018 (7 years ago)	Expired
US6147103	Omeprazole process and compositions thereof	09 Oct, 2018 (7 years ago)	Expired
US6166213	Omeprazole process and compositions thereof	09 Oct, 2018 (7 years ago)	Expired
US6191148	Omerazole process and compositions thereof	09 Oct, 2018 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prilosec's drug page

26. Prilosec Otc

Prilosec Otc is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6403616	Chemical process and pharmaceutical formulation	15 Nov, 2019 (6 years ago)	Expired
US6428810	Pharmaceutical formulation comprising omeprazole	03 Nov, 2019 (6 years ago)	Expired
US5900424	Omeprazole magnesium salt form	04 May, 2016 (10 years ago)	Expired
US5817338	Multiple unit tableted dosage form of omeprazole	06 Oct, 2015 (11 years ago)	Expired
US5753265	Multiple unit pharmaceutical preparation	07 Jun, 2015 (11 years ago)	Expired
US5690960	Pharmaceutical formulation of omeprazole	25 Nov, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prilosec Otc's drug page

27. Pulmicort Respules

Pulmicort Respules is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6598603 (Pediatric)	Method for treating respiratory diseases	23 Jun, 2019 (7 years ago)	Expired
US6899099 (Pediatric)	Method for treating a respiratory disease	23 Jun, 2019 (7 years ago)	Expired
US7524834 (Pediatric)	Sterile powders, formulations, and methods for producing the same	11 May, 2019 (7 years ago)	Expired
US6598603	Method for treating respiratory diseases	23 Dec, 2018 (7 years ago)	Expired
US6899099	Method for treating a respiratory disease	23 Dec, 2018 (7 years ago)	Expired
US7524834	Sterile powders, formulations, and methods for producing the same	11 Nov, 2018 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pulmicort Respules's drug page

28. Qtern

Qtern is protected by 17 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7919598 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Jun, 2030 (3 years from now)	Active
US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Dec, 2029 (3 years from now)	Active
US8221786 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US8361972 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US8716251 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US8221786	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8361972	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8716251	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8501698 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Dec, 2027 (1 year, 2 months from now)	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Jun, 2027 (8 months from now)	Active
US6515117 (Pediatric)	C-aryl glucoside SGLT2 inhibitors and method	04 Apr, 2026 (5 months ago)	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2025 (11 months ago)	Expired
US8628799	Coated tablet formulation and method	13 Jul, 2025 (1 year, 2 months ago)	Expired
USRE44186	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	31 Jul, 2023 (3 years ago)	Expired
US6414126	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US6936590	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	04 Oct, 2020 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qtern's drug page

29. Qternmet Xr

Qternmet Xr is protected by 15 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9616028 (Pediatric)	Bilayer tablet formulations	12 May, 2031 (4 years from now)	Active
US9616028	Bilayer tablet formulations	12 Nov, 2030 (4 years from now)	Active
US7919598 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Jun, 2030 (3 years from now)	Active
US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Dec, 2029 (3 years from now)	Active
US8716251 (Pediatric)	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Sep, 2028 (1 year, 11 months from now)	Active
US8716251	Pharmaceutical formulations containing an SGLT2 inhibitor	21 Mar, 2028 (1 year, 5 months from now)	Active
US8501698 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Dec, 2027 (1 year, 2 months from now)	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Jun, 2027 (8 months from now)	Active
US6515117 (Pediatric)	C-aryl glucoside SGLT2 inhibitors and method	04 Apr, 2026 (5 months ago)	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2025 (11 months ago)	Expired
US8628799	Coated tablet formulation and method	13 Jul, 2025 (1 year, 2 months ago)	Expired
USRE44186	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method	31 Jul, 2023 (3 years ago)	Expired
US6414126	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US6936590	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	04 Oct, 2020 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qternmet Xr's drug page

30. Rhinocort

Rhinocort is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6291445 (Pediatric)	Low dose budesonide formulations and uses thereof	29 Oct, 2017 (8 years ago)	Expired
US6686346 (Pediatric)	Formulation	29 Oct, 2017 (8 years ago)	Expired
US6986904 (Pediatric)	Formulation	29 Oct, 2017 (8 years ago)	Expired
US6291445	Low dose budesonide formulations and uses thereof	29 Apr, 2017 (9 years ago)	Expired
US6686346	Formulation	29 Apr, 2017 (9 years ago)	Expired
US6986904	Formulation	29 Apr, 2017 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rhinocort's drug page

31. Symbicort

Symbicort is protected by 33 patents, out of which 26 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8616196 (Pediatric)	Inhalation device and a method for assembling said inhalation device	07 Oct, 2029 (3 years from now)	Active
US8528545 (Pediatric)	Inhaler device that reduces the risk for miscounting a dosage	16 Apr, 2029 (2 years from now)	Active
US8616196	Inhalation device and a method for assembling said inhalation device	07 Apr, 2029 (2 years from now)	Active
US8528545	Inhaler device that reduces the risk for miscounting a dosage	16 Oct, 2028 (2 years from now)	Active
US8387615 (Pediatric)	Inhaler cap strap	26 Sep, 2027 (11 months from now)	Active
US8387615	Inhaler cap strap	26 Mar, 2027 (5 months from now)	Active
US7587988 (Pediatric)	Inhaler device counter	10 Oct, 2026 (6 days from now)	Active
US7587988	Inhaler device counter	10 Apr, 2026 (5 months ago)	Expired
US8875699 (Pediatric)	Inhaler cap strap	10 May, 2025 (1 year, 4 months ago)	Expired
US8875699	Inhaler cap strap	10 Nov, 2024 (1 year, 10 months ago)	Expired
US10166247 (Pediatric)	Composition for inhalation	29 Jul, 2023 (3 years ago)	Expired
US11311558 (Pediatric)	Composition for inhalation	29 Jul, 2023 (3 years ago)	Expired
US7759328 (Pediatric)	Composition for inhalation	29 Jul, 2023 (3 years ago)	Expired
US8143239 (Pediatric)	Composition for inhalation	29 Jul, 2023 (3 years ago)	Expired
US8575137 (Pediatric)	Composition for inhalation	29 Jul, 2023 (3 years ago)	Expired
US10166247	Composition for inhalation	29 Jan, 2023 (3 years ago)	Expired
US11311558	Composition for inhalation	29 Jan, 2023 (3 years ago)	Expired
US7759328	Composition for inhalation	29 Jan, 2023 (3 years ago)	Expired
US8143239	Composition for inhalation	29 Jan, 2023 (3 years ago)	Expired
US8575137	Composition for inhalation	29 Jan, 2023 (3 years ago)	Expired
US7967011 (Pediatric)	Inhalation device	11 Feb, 2022 (4 years ago)	Expired
US7967011	Inhalation device	11 Aug, 2021 (5 years ago)	Expired
US7367333 (Pediatric)	Inhalation device	11 May, 2019 (7 years ago)	Expired
US7897646 (Pediatric)	Use for budesonide and formoterol	09 Mar, 2019 (7 years ago)	Expired
US8461211 (Pediatric)	Use for budesonide and formoterol	09 Mar, 2019 (7 years ago)	Expired
US7367333	Inhalation device	11 Nov, 2018 (7 years ago)	Expired
US7897646	Use for budesonide and formoterol	09 Sep, 2018 (8 years ago)	Expired
US8461211	Use for budesonide and formoterol	09 Sep, 2018 (8 years ago)	Expired
US6123924 (Pediatric)	Pressurized aerosol inhalation compositions	26 Mar, 2018 (8 years ago)	Expired
US6123924	Pressurized aerosol inhalation compositions	26 Sep, 2017 (9 years ago)	Expired
US5674860	Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders	07 Oct, 2014 (11 years ago)	Expired
US5972919	Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof	17 Dec, 2012 (13 years ago)	Expired
US6641800	Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane	23 Sep, 2012 (14 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symbicort's drug page

32. Symbicort Aerosphere

Symbicort Aerosphere is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10716753	Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems	28 May, 2030 (3 years from now)	Active
US9415009	Compositions, methods and systems for respiratory delivery of two or more active agents	28 May, 2030 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symbicort Aerosphere's drug page

33. Symlin

Symlin is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5686411	Amylin agonist peptides and uses therefor	16 Mar, 2019 (7 years ago)	Expired
US6114304	Methods for regulating gastrointestinal motility	05 Sep, 2017 (9 years ago)	Expired
US5814600	Method and composition for treatment of insulin requiring mammals	29 Sep, 2015 (11 years ago)	Expired
US6608029	Methods for regulating gastrointestinal motility	07 Sep, 2013 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symlin's drug page

34. Tagrisso

Tagrisso is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12465608	Osimertinib For Use In The Treatment Of Non-Small Cell Lung Cancer	26 Nov, 2042 (16 years from now)	Active
US10183020	Pharmaceutical compositions comprising AZD9291	02 Jan, 2035 (8 years from now)	Active
US8946235	2-(2,4,5-substituted-anilino) pyrimidine compounds	08 Aug, 2032 (5 years from now)	Active
US11524951	2-(2,4,5-substituted-anilino)pyrimidine compounds	25 Jul, 2032 (5 years from now)	Active
US9732058	2-(2,4,5-substituted-anilino)pyrimidine compounds	25 Jul, 2032 (5 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tagrisso's drug page

35. Truqap

Truqap is protected by 11 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10039766	Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide	16 Apr, 2033 (6 years from now)	Active
US9487525	Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide	16 Apr, 2033 (6 years from now)	Active
US8101623	Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor	10 Mar, 2030 (3 years from now)	Active
US10059714	Protein kinase B inhibitors	10 Oct, 2028 (2 years from now)	Active
US10654855	Protein kinase B inhibitors	10 Oct, 2028 (2 years from now)	Active
US11236095	Protein Kinase B Inhibitors	10 Oct, 2028 (2 years from now)	Active
US11760760	Protein kinase B inhibitors	10 Oct, 2028 (2 years from now)	Active
US12252495	Protein kinase B inhibitors	10 Oct, 2028 (2 years from now)	Active
US9492453	Protein Kinase B Inhibitors	10 Oct, 2028 (2 years from now)	Active
US8809336	Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors	25 Oct, 2025 (11 months ago)	Expired
US9006430	Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein	25 Oct, 2025 (11 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Truqap's drug page

36. Wainua

Wainua is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10683499	Compositions and methods for modulating TTR expression	25 Aug, 2034 (7 years from now)	Active
US9127276	Conjugated antisense compounds and their use	01 May, 2034 (7 years from now)	Active
US9181549	Conjugated antisense compounds and their use	01 May, 2034 (7 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wainua's drug page

37. Wainua (autoinjector)

Wainua (autoinjector) is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10683499	Compositions and methods for modulating TTR expression	25 Aug, 2034 (7 years from now)	Active
US9127276	Conjugated antisense compounds and their use	01 May, 2034 (7 years from now)	Active
US9181549	Conjugated antisense compounds and their use	01 May, 2034 (7 years from now)	Active
US8101743	Modulation of transthyretin expression	01 Apr, 2026 (6 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wainua (autoinjector)'s drug page

38. Xigduo Xr

Xigduo Xr is protected by 13 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9616028 (Pediatric)	Bilayer tablet formulations	12 May, 2031 (4 years from now)	Active
US8685934 (Pediatric)	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	26 Nov, 2030 (4 years from now)	Active
US9616028	Bilayer tablet formulations	12 Nov, 2030 (4 years from now)	Active
US7919598 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Jun, 2030 (3 years from now)	Active
US8685934	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	26 May, 2030 (3 years from now)	Active
US7919598	Crystal structures of SGLT2 inhibitors and processes for preparing same	16 Dec, 2029 (3 years from now)	Active
US8501698 (Pediatric)	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Dec, 2027 (1 year, 2 months from now)	Active
US8501698	Crystal structures of SGLT2 inhibitors and processes for preparing same	20 Jun, 2027 (8 months from now)	Active
US6515117 (Pediatric)	C-aryl glucoside SGLT2 inhibitors and method	04 Apr, 2026 (5 months ago)	Expired
US6515117	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2025 (11 months ago)	Expired
US6414126	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US6936590	C-aryl glucoside SGLT2 inhibitors and method	04 Oct, 2020 (6 years ago)	Expired
US9198925	Pharmaceutical formulations containing an SGLT2 inhibitor	04 Oct, 2020 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xigduo Xr's drug page

39. Zomig-zmt

Zomig-zmt is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5466699 (Pediatric)	Indolyl compounds for treating migraine	14 May, 2013 (13 years ago)	Expired
US5466699	Indolyl compounds for treating migraine	14 Nov, 2012 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zomig-zmt's drug page

Pharsight

Pharsight

Latest Legal Activities on Astrazeneca's Drug Patents

Astrazeneca's Drug Patent Litigations

Astrazeneca Drug Patents' Oppositions Filed in EPO

Astrazeneca's Family Patents

Clinical Trials

Recent Clinical Trials by Astrazeneca:

Astrazeneca Drug List

Explore Our Curated Drug Screens

Related content

Have Questions?